Fluoguide AS
STO:FLUO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.9
75.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Common Stock
Fluoguide AS
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
F
|
Fluoguide AS
STO:FLUO
|
Common Stock
kr1.2m
|
CAGR 3-Years
5%
|
CAGR 5-Years
89%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Common Stock
kr66m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
||
Zealand Pharma A/S
CSE:ZEAL
|
Common Stock
kr71m
|
CAGR 3-Years
18%
|
CAGR 5-Years
15%
|
CAGR 10-Years
12%
|
||
Ascendis Pharma A/S
NASDAQ:ASND
|
Common Stock
€2.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
229%
|
CAGR 10-Years
111%
|
||
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Common Stock
kr781.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
Bioporto A/S
CSE:BIOPOR
|
Common Stock
kr429.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
20%
|
CAGR 10-Years
14%
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Common Stock?
Common Stock
1.2m
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Common Stock amounts to 1.2m DKK.
What is Fluoguide AS's Common Stock growth rate?
Common Stock CAGR 5Y
89%
Over the last year, the Common Stock growth was 3%. The average annual Common Stock growth rates for Fluoguide AS have been 5% over the past three years , 89% over the past five years .